1. 主要醫療科技評估組織，除加拿大 CADTH，其餘皆有公告本案藥品之相關
(1) 澳洲 PBAC 同意收載 trastuzumab SC 皮下注射劑用於 HER2 陽性早期乳 癌、局部晚期乳癌和轉移性（第四期）乳癌病人。PBAC 認為整體而言，
最差的情況即為與原先僅收載 trastuzumab IV 時相比無財務影響，但應 監測用量，若 trastuzumab SC 後續用量過高，應降低價格。
(2) 英國 NICE 尚未發表完整之評估報告(guidance)，而 2013 年發表之實證 整理(evidence summary)指出在估算 trastuzumab SC 可能節省的成本 時，需注意以取代藥品 trastuzumab IV 在病人體重及開瓶浪費問題。
(3) 蘇格蘭 SMC 同意 trastuzumab SC 為具費用節省的治療選項，同意比照 trastuzumab IV 用於英國國民健康服務蘇格蘭系統（NHS Scotland）。 2. 於 PubMed、Embase、Cochrane、CRD、INAHTA 等文獻資料庫搜尋本案藥
品，經標題、摘要閱讀後，共查獲 6 篇相關之經濟評估研究；此 6 篇研究之 研究設計均為成本比較或最低成本分析，研究結果大致顯示 trastuzumab SC 的治療成本較 trastuzumab IV 低，而病人體重是影響分析結果的敏感因子。
3. 財務影響方面，本報告預估 trastuzumab（Herceptin
®
）SC 皮下注射劑納入健 保給付後，基礎方案分析以取代率 75%計算，Herceptin®
SC 使用量由第一 年約 26,000 瓶至第五年約 37,000 瓶，年度藥費第一年約 13 億元至第五年約 18.1 億元，扣除取代藥品費用後，財務影響第一年節省約 2.5 億元至第五年 節省約 3.6 億元。另敏感度分析顯示，當取代率為 65%時，預估 Herceptin®
SC 的財務影響第一年節省約 2.2 億元至第五年節省約 3.1 億元，當取代率為 85%時，預估 Herceptin
®
SC 的財務影響第一年節省約 2.9 億元至第五年節省約 4 億元。1. 台灣癌症臨床研究發展基金會. 認識乳癌. 台灣癌症臨床研究發展基金會.
Published 2017. Accessed January 02, 2018.
2. 國家衛生研究院. TCOG 乳癌診斷與治療共識. In: 癌症研究組 國, ed.
http://www.nhri.org.tw/NHRI_ADM/userfiles/file/tcog/breast_II.pdf: 國家衛
生研究院; 2004.3. Organization WH. GLOBOCAN 2012 Breast Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012. WHO. Published 2012.
Accessed January 02, 2018.
4. 衛生福利部國民健康署. 中華民國 104 年癌症登記報告 In: 衛生福利部 國民健康署, ed.
https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=8084: 衛生福利
部 2017.5. 衛生福利部. 105 年國人死因統計結果. 衛生福利部統計處. Published 2017.
Accessed January 02, 2018.
6. 財團法人醫藥品查驗中心. 法洛德注射液 50 毫克/毫升(Faslodex) 醫療科 技評估報告. In: 衛生福利部國民健康保險署, ed.; 2016.
7. Institute NC. NCI Dictionary of Cancer Terms. Published 2018. Accessed January 03, 2018.
8. Network MBC. Understanding Metastatic Breast Cancer. Published 2017.
Accessed January 03, 2018.
9. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Archives of pathology & laboratory medicine 2014; 138(2):
241-256.
10. Society AC. UNDERSTANDING A BREAST CANCER DIAGNOSIS.
Published 2017. Accessed January 04, 2018.
11. NCCN. NCCN Clinical Practice Guidelines in Oncology, Breast Cancer Version 2. 2017. NCCN. Published 2017. Accessed January 12, 2018.
12. Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of
oncology : official journal of the European Society for Medical Oncology
2015; 26 Suppl 5: v8-30.13. Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Annals of oncology : official
journal of the European Society for Medical Oncology 2017; 28(12): 3111.
04, 2018.
15. Methodology WCCfDS. ATC/DDD Index 2018. Published 2018. Accessed January 8, 2018.
16. 衛生福利部食品藥物管理署. 西藥、醫療器材、含藥化粧品許可證查詢.
Published 2018. Accessed January 8, 2018.
17. CADTH. CADTH. Published 2018. Accessed January 10, 2018.
18. PBAC. TRASTUZUMAB, 600 mg/5 mL solution for subcutaneous injection, Herceptin® SC, Roche. Published 2015. Accessed January 10, 2018.
19. NICE. Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM 13). Published 2013. Accessed January 10, 2018.
20. SMC. trastuzumab, 600mg/5mL solution for injection (Herceptin® ) SMC No.
(928/13) Published 2013. Accessed January 10, 2018.
21. Pivot X, Spano JP, Espie M, et al. Patients' preference of trastuzumab
administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study. European journal
of cancer (Oxford, England : 1990) 2017; 82: 230-236.
22. Pivot X, Gligorov J, Muller V, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. The Lancet
Oncology 2013; 14(10): 962-970.
23. Pivot X, Gligorov J, Muller V, et al. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Annals of
oncology : official journal of the European Society for Medical Oncology
2014; 25(10): 1979-1987.24. Pivot X, Verma S, Fallowfield L, et al. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study. European journal of cancer (Oxford, England :
1990) 2017; 86: 82-90.
25. Gligorov J, Curigliano G, Muller V, et al. Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial. Breast
(Edinburgh, Scotland) 2017; 34: 89-95.
26. Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label,
27. Jackisch C, Kim SB, Semiglazov V, et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Annals of oncology : official journal
of the European Society for Medical Oncology 2015; 26(2): 320-325.
28. Jackisch C, Hegg R, Stroyakovskiy D, et al. HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with
neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.